Medwiz Pharmaceuticals Private Limited
Medwiz Pharmaceuticals Private Limited is a Private Non-govt company company incorporated in 2016 and based in Delhi, India. It was founded by Rakesh and Narottam. Medwiz Pharmaceuticals Private Limited operates in E-commerce facility employed in wholesale (NIC 51902) with authorized capital of ₹1.00 L and paid-up capital of ₹1.00 L. For 2022-23, the company reported revenue of ₹0 and a net loss of ₹7.5K. The board has 4 active directors. RegisterKaro's provisional Compliance Health Score for the company is 100/100 (grade A), based on 4 of 9 signals — full scoring is pending extraction of the company's MCA filing history.
Explore the financials, board members, legal insights, and much more in the complete profile of MEDWIZ PHARMACEUTICALS PRIVATE LIMITED.
Quick facts
Directors
4 activeMCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | 0d | filed |
| MGT-7 | FY2024-25 | 20 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | 0d | filed |
| MGT-7 | FY2023-24 | 24 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 21 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Medwiz Pharmaceuticals Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 708158437 | HDFC Bank Ltd(Bank) | ₹16.02 Cr | 12 Mar 2023 | Open |
| 966097872 | ICICI Bank Ltd(Bank) | ₹16.78 Cr | 27 Jan 2022 | Satisfied |
| 699708535 | State Bank of India(Bank) | ₹9.43 Cr | 12 Mar 2023 | Open |
| 561845033 | ICICI Bank Ltd(Bank) | ₹12.35 Cr | 19 Sep 2020 | Satisfied |
Charge IDs, lenders & amounts for Medwiz Pharmaceuticals Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2022-23 | — | ||||
| 2020-21 | — | ||||
| 2019-20 | — | ||||
| 2018-19 | — | ||||
| 2017-18 | — | ||||
| 2016-17 | — |
Detailed Financials
4 FYs| Line item | 2022-23 | 2020-21 | 2019-20 | 2018-19 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ||||
| Other income | ||||
| Total income | ||||
| Total expenses | ||||
| Profit before tax | ||||
| Profit / (Loss) after tax | ||||
| Balance sheet | ||||
| Equity / Net worth | ||||
| Borrowings | ||||
| Current liabilities | ||||
| Total liabilities | ||||
| Current assets | ||||
| Cash & equivalents | ||||
| Total assets | ||||
| Employees | — | — | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2022-23 | — | — | — | |
| Profit after Tax2022-23 | — | — | — | |
| Net Worth2022-23 | — | — | — |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2016-17 | — | — | -144.62% | -134.73% | 1.07 | |||
| 2017-18 | — | — | -53.49% | -41.74% | 1.28 | |||
| 2018-19 | — | — | -95.21% | -61.44% | 1.55 | |||
| 2019-20 | — | — | -1986.24% | -82.98% | 23.94 | |||
| 2020-21 | — | — | — | -299.95% | — | |||
| 2022-23 | — | — | — | -191.62% | — |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 1 | 3,75,99,130 | 81.31% |
| Institutional Investors | 1 | 22,42,108 | 4.85% |
| Public & Others | 49 | 64,01,882 | 13.84% |
Promoter, institutional & public holding for Medwiz Pharmaceuticals Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
12 peersEvents & timeline
5External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.